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Background:  Ginkgo  biloba  extract  (GBE),  a traditional  natural  herbal  product,  is often  used in the  treat-
ment  of  essential  hypertension  (EH)  as complementary  therapy  in  China  and European  countries.
Aim:  To  critically  assess  the current  clinical  evidence  of  efﬁcacy  and  safety  of  GBE  for  EH.
Methods:  7 electronic  databases  (Cochrane  Library,  PubMed,  EMBASE,  VIP,  CBM,  Wanfang  data,  and  CNKI)
were searched  to identify  randomized  controlled  trials  (RCTs)  of GBE  for EH.  Methodological  quality  was
assessed  independently  using  the Cochrane  Handbook  for Systematic  Reviews  of  Interventions.
Results: A  total  of  9 RCTs  with  1012  hypertensive  patients  were  identiﬁed  and  reviewed.  Most  RCTs  were
of  high  risk of bias  with  ﬂawed  study  design  and  poor  methodological  quality.  6  trials  demonstrated
potential  positive  effect  of  GBE  as complementary  therapy  on BP  reduction  when compared  with  antihy-
pertensive  drug  therapy;  however,  it was  not  associated  with  a statistically  signiﬁcant  effect  on both  SBP
and  DBP  reduction  in 3 other trials.  Despite  the  positive  ﬁndings,  there  were  so  many  methodological
limitations  and  signiﬁcant  clinical  heterogeneity.  Most  of  the trials did  not  report  adverse  effects,  and  the
safety  of  GBE  is still  uncertain.
Conclusion:  No  conﬁrmative  conclusions  on the  efﬁcacy  and  safety  of  GBE  for  EH  could be drawn.  More
rigorous  trials  are  warranted  to  support  their  clinical  use.
© 2014  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Hypertension is an important worldwide public-health chal-
enge, which can lead to severe complications and target organ
amage (Karen et al. 2011). Oral antihypertensive drugs, lifestyle
odiﬁcation including exercise and dietary modiﬁcation are mile-
tones for hypertension therapy (Chobanian et al. 2003). However,
he control rate of hypertension has not reached the expected
equirements (Redwood 2007). Thus, a certain proportion of hyper-
ensive patients has turned to traditional medicine (TM) (Ernst
005), including traditional Chinese medicine (TCM) (Wang and
iong 2012a), for better clinical efﬁciency in lowing blood pressure
BP) smoothly and improving uncontrolled hypertension-related
ymptoms (including headache, dizziness, fatigue, etc.) with lit-
le adverse effects (Mansoor 2001). Over the past 30 years, study
n Chinese herbal medicine (CHM) for hypertension is the most
ctive area of research within TCM and integrative medicine in
hina (Xiong et al. 2013). Currently, more and more randomized
ontrolled trials (RCTs) and systematic reviews (SRs) have been
onducted, which have paved the evidenced-based way in mak-
ng recommendation for TCM physicians, hypertensive patients
nd policy makers (Wang and Xiong 2012b). It is demonstrated
hat CHM as complementary therapy appears to be more effective
n reducing BP and relieving signs and symptoms in hypertensive
atients (Wang and Xiong 2013).
Ginkgo biloba extract (GBE), made from the dried leaves of the
inkgo tree, is one of the top sellers within the growing market
or herbal remedies in many European countries as well as in the
SA (Kressmann et al. 2002b). The chemical composition of GBE
s complex and several of its constituents (e.g. ﬂavone glycosides
nd terpenoids) have been proposed as being responsible for the
ardiovascular protective effects and cerebrovascular-related dis-
rders (Gaby 1996). In European countries, GBE shows promise
n treating dementia and aging-associated cognitive impairment,
ertigo, tinnitus, and peripheral arterial disease (Diamond et al.
000). In China, the therapeutic indications of GBE described in
harmacopeia of People’s Republic of China (2010 edition)  include
hest impediment, heart pain, stroke, hemiplegia and dysphasia
ue to blockage of meridians by stagnated blood; angina pectoris
f the stable type in coronary heart disease and cerebral infarction
ith above symptoms (National Pharmacopoeia Committee 2010).
lthough it is not used to treat hypertension in Western countries
nd China regularly, several studies did suggest antihypertensive
ffect both in vitro and in vivo, providing a possible alternative
echanism for cardiovascular disease prevention (Kudolo 2000). In
ypertensive rats models, treatment with GBE attenuated the rise
n BP (Sasaki et al. 2002), the mechanism of which may  be related to
nhibiting angiotensin converting enzyme activity, preserving vas-
ular reactivity toward endothelium-dependent and -independent
asodilators, inhibit responses to vasoconstrictors, etc. (Mansour
t al. 2011; Kubota et al. 2006). However, it is worth noting that
ifferences in quality and composition may  affect the bioavailabil-
ty and therefore the biological effects of the active molecules in
n extract (Kressmann et al. 2002a; Itil and Martorano 1995). 1
rial in 3069 elderly subjects did not ﬁnd any difference between
inkgo leaf extract EGb 761® and placebo with respect to changes
n BP, neither in the normotensive nor in hypertensive participants
Brinkley et al. 2010). Therefore, whether GBE can be recommended
or routine use based on the current evidence is still uncertain.
In this review, only GBE, containing total ﬂavonol glycosides
.6 mg  and terpene lactones 2.4 mg  in each tablet, could be included
or further analysis. As a pure extracts of Ginkgo biloba leaves, it
as been approved by the China Food and Drug Administration
available in http://www.sda.gov.cn). It is also known as Ginkgo leaf
ablet, a popular Chinese patent medicine (CPM) which have been
ubjected to a relatively strict drug evaluation process includinge 21 (2014) 1131–1136
active constitutes identiﬁcation, compatibility mechanism study,
efﬁciency and safety evaluation, and RCTs. This SR is aimed at crit-
ically evaluating the data from RCTs of GBE for EH to provide the
best available evidence for clinical practice and further research
planning on EH.
Methods
Database and search strategies
Literature searches were conducted in the following 7 elec-
tronic databases: Cochrane Library (November, 2013), PubMed
(1959–2013), EMBASE (1980–2013), Chinese National Knowl-
edge Infrastructure (CNKI, 1979–2013), Chinese Scientiﬁc Jour-
nal Database (VIP, 1989–2013), Chinese Biomedical Literature
Database (CBM, 1978–2013) and Wanfang data (1998–2013). As
GBE is used and researched in China, 4 main databases in Chi-
nese language were searched to retrieve the maximum possible
number of clinical trials. Literature searches were ended on 17
November, 2013. Ongoing registered trials were searched in the
website of Chinese clinical trial registry (http://www.chictr.org/)
and international clinical trial registry by U.S. National Institutes of
Health (http://clinicaltrials.gov/). The following search terms were
used individually or combined: ‘Ginkgo biloba extract’, ‘Ginkgo
biloba leaf extract’, ‘Ginkgo leaf extract’, ‘Ginkgo leaf tablet’, ‘yin
xing ye tablet’, ‘yinxingye tablet’, ‘yin xing ye pill’, ‘yinxingye pill’,
‘yin xing ye pian’, ‘yinxingye pian’, ‘hypertension’, ‘essential hyper-
tension’, ‘blood pressure’, ‘high blood pressure’, ‘clinical trial’, and
‘randomized controlled trial’. Reference lists of retrieved papers
were searched as well.
Inclusion criteria
We  included all parallel RCTs comparing GBE as monotherapy
or adjunct therapy to conventional medicine with antihyperten-
sive drugs for EH, which used BP reduction as the main outcome
measure with no restrictions on population characteristics, lan-
guage and publication type. Interventions in either experimental or
control group including other CHM were excluded. Interventions
in control group should include no treatment, placebo, and con-
ventional medicine (antihypertensive drugs). Quasi randomized
trials and animal experiments were also excluded as well. Dupli-
cated publications reporting the same groups of participants were
excluded. Participants with EH should meet the following diag-
nostic criteria: systolic blood pressure (SBP) ≥ 140 mmHg, and/or,
diastolic blood pressure (DBP) ≥ 90 mmHg. There is no restriction
on dosage including frequency, dose, and intensity. Duration of
treatment courses should be more than 4 weeks.
Data extraction and quality assessment
Two authors independently conducted the literature search-
ing (Xiong X, Yang X), study selection (Liu W,  Feng B), and data
extraction (Zhang Y, Li S). According to the predeﬁned criteria,
extracted data information included authors, title of study, year
of publication, study size, age and sex of the participants, details
of methodological information, treatment process, details of the
control interventions, outcome measures, and adverse effects for
each study. Disagreement was  resolved by discussion and reached
consensus through a third party (Li XK, Wang J).
To assess the methodological quality, the Cochrane Handbook
for Systematic Review of Interventions, Version 5.1.0 was used
(Higgins and Green 2011). The items included the following 7
aspects: random sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and person-
nel (performance bias), blinding of outcome assessment (detection
X.J. Xiong et al. / Phytomedicin
b
t
i
(
w
(
i
w
b
D
p
D
o
i
a
r
i
d
(
a
R
D
s
w
C
e
i
o
aFig. 1. PRISMA 2009 ﬂow diagram.
ias), incomplete outcome data (attrition bias), selective repor-
ing (reporting bias), and other bias. Methodological quality of all
ncluded trials was categorized to low/unclear/high risk of bias
“Yes” for a low of bias, “No” for a high risk of bias, “Unclear” other-
ise). Then trials were categorized into three levels: low risk of bias
all the items were in low risk of bias), high risk of bias (at least one
tem was in high risk of bias), unclear risk of bias (at least one item
as in unclear). Discrepancies were resolved through discussion
etween the authors.
ata synthesis
Two researchers (Xiong X, Yang X) used Review Manager 5.1,
rovided by the Cochrane corporative network, to analyze the data.
ichotomous data were presented as risk ratio (RR) and continu-
us outcomes as mean difference (MD), both with 95% conﬁdence
nterval (CI). The chi-square test was used to test heterogeneity
cross studies with a signiﬁcance level of 0.05. Heterogeneity was
ecognized signiﬁcant when I2 ≥ 50%. Fixed effects model was used
f there is no signiﬁcant heterogeneity of the data (I2 < 50%); ran-
om effects model was used if signiﬁcant heterogeneity existed
50% < I2 < 85%). Publication bias would be explored by funnel plot
nalysis if sufﬁcient studies were found.
esults
escription of included trials
As shown in Fig. 1, a ﬂow chart depicted the search process and
tudy selection. Finally, 9 studies with 1012 hypertensive patients
ere included for analysis (Chen 2011; Ge and Pan 2008; Guo and
hen 2013; Liu et al. 2010; Tu and Zhou 2007; Wang et al. 2012; Xu
t al. 2008; Yu 1999; Zhou et al. 2007). All studies were conducted
n China and published in Chinese (1999–2013). The characteristics
f 9 trials were listed in Table 1.
Among them, 4 diagnostic criteria of EH were speciﬁed. 2 tri-
ls (Tu and Zhou 2007; Zhou et al. 2007) used Chinese Guidelinese 21 (2014) 1131–1136 1133
for the Management of Hypertension-1999 (CGMH-1999), 2 trials
(Liu et al. 2010; Wang et al. 2012) used Chinese Guidelines for the
Management of Hypertension-2005 (CGMH-2005), 2 trials (Ge and
Pan 2008; Guo and Chen 2013) used WHO-ISH guidelines for the
management of hypertension-1999 (WHO-ISH GMH-1999), 1 trial
used Practice of Internal Medicine (10th edition), and 2 trials (Chen
2011; Xu et al. 2008) only demonstrated patients with EH without
detailed information.
Interventions of all trials included GBE combined with antihy-
pertensive drugs. Controls included antihypertensive drugs alone.
Total treatment course duration ranged from 8 weeks to 6 months.
All of them used BP as the outcome measure. Adverse effect was
also described in details.
Methodological quality of included trials
Methodological quality of most trials was  evaluated to be gen-
eral low according to the predeﬁned quality assessment criteria. All
trials declared that hypertensive patients were randomly assigned
to the experimental group and control group; however, only 1 trial
has described method for random sequence generation (random
number table) (Guo and Chen 2013). Allocation concealment and
double-blind were not reported in all trials. Only 1 trial reported
drop-out (Liu et al. 2010). No trial reported a pre-trial estimation
of sample size.
Effect of the interventions
3 grades, which were authoritatively recommended by Guide-
lines of Clinical Research of New Drugs of Traditional Chinese
Medicine (GCRNDTCM), were used to evaluate the therapeutic
effects of GBE for EH in 6 trials (Chen 2011; Liu et al. 2010; Tu and
Zhou 2007; Xu et al. 2008; Yu 1999; Zhou et al. 2007). Detailed
information about 3 classiﬁcations were described as follows:
“signiﬁcant improvement” (DBP decreased by 10 mmHg reaching
the normal range, or, DBP has not yet returned to normal, but
has been reduced ≥20 mmHg), “improvement” (DBP decreased to
less than 10 mmHg  reaching the normal range, or, DBP decreased
by 10–19 mmHg, but did not reach the normal range, or, SBP
decreased ≥30 mmHg), and “no improvement” (not to meet the
above standards) (Xiong et al. 2014). To permit at least some over-
all analysis, these outcomes were converted into dichotomous
data. We  grouped together both “signiﬁcant improvement” and
“improvement” as “effective”, and “no improvement” as “ineffec-
tive”. Meta-analysis showed that BP is signiﬁcantly decreased in
experimental group at the end of treatment (RR: 1.08 [1.02, 1.14];
P = 0.01) (Fig. 2).
3 trials (Ge and Pan 2008; Guo and Chen 2013; Wang et al. 2012)
used BP values to assess the therapeutic effect of GBE for EH. When
it comes to SBP, signiﬁcant homogeneity in the trial was found, chi-
square = 16.32 (p = 0.0003); I2 = 88%. Thus, random effects model
was used for statistical analysis. Meta-analysis showed there is no
signiﬁcant difference between experimental and control group on
SBP (MD: −4.37 [−11.20, 2.45]; p = 0.21) (Fig. 3). When it comes
to DBP, there is also signiﬁcant homogeneity, chi-square = 7.54
(p = 0.02); I2 = 73%. Therefore, random effects model was  used for
statistical analysis. No signiﬁcant difference between experimen-
tal and control group on DBP (MD: −3.09 [−6.50, 0.33]; p = 0.08)
was found (Fig. 4).Publication bias
The number of included trials in this review was too small to
conduct any sufﬁcient additional analysis of publication bias.
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Table 1
Characteristics of included trials.
Study ID Sample size (randomized/
analyzed) M/F
Age (yrs) Diagnosis standard Intervention Control Course Outcome
measure
Xu et al. (2008) 220/220 60–82 Hypertension
diagnostic criteria
(unclear)
GBE (1# tid)
+  control
Amlodipine (5 mg qd) 6 months BP
T:  115 (T/C: NR)
C: 105
Chen (2011) 120/120 T: 59.8 ± 5.2 Hypertension
diagnostic criteria
(unclear)
GBE (1# tid)
+  control
Antihypertensive drugs
(no detailed
information)
6 months BP
T:  34/26 C: 60.1 ± 4.8
C:  33/27
Zhou et al. (2007) 116/116 T: 49.7 ± 3.2 CGMH-1999 GBE (2# tid)
+  control
Metoprolol (100 mg
bid)
24 weeks BP
T:  36/20 C: 48.7 ± 3.0
C: 40/20
Liu et al. (2010) 123/116 60–82 CGMH-2005 GBE (2# tid)
+  control
Metoprolol
(50 mg qd/bid)
24 weeks BP
T:  36/20 (T/C: NR)
C: 40/20
Yu (1999) 50/50 NR Practice of Internal
Medicine (10th
edition)
GBE (1# tid)
+  control
Capoten (6.25–25 mg
tid)
6 months BP
T:  30
C: 20
Tu and Zhou (2007) 58/58 T: 49.7 ± 3.2 CGMH-1999 GBE (2# tid)
+  control
Metoprolol (100 mg
bid)
24 weeks BP
T:  18/10 C: 48.7 ± 3.0
C: 20/10
Wang et al. (2012) 152/152 60–75 CGMH-2005 GBE (2# tid)
+  control
Valsartan (80–160 mg
qd)
6 months BP; adverse
effectT:  76 (T/C: NR)
C: 76
Guo and Chen (2013) 84/84 T: 68.8 ± 7.7 WHO-ISH GMH-1999 GBE (19.6 mg tid)
+ control
Amlodipine besylate
tablets
(5 mg qd)
8 weeks BP
T:  20/22 C: 67.5 ± 7.4
C: 21/21
Ge and Pan (2008) 96/96 52–82 WHO-ISH GMH-1999 GBE (80 mg tid)
+ control
Amlodipine besylate
tablets
(2.5 mg qd)
6 months BP; adverse
effectT:  25/23 (T/C: NR)
C: 26/22
Abbreviations: T: treatment group; C: control group; NR: not reported; BP: blood pressure; CGMH: Chinese Guidelines for the Management of Hypertension; WHO-ISH GMH:
WHO-ISH guidelines for the management of hypertension; #: tablet; GBE: a pure extracts of Ginkgo biloba leaves containing total ﬂavonol glycosides 9.6 mg and terpene
lactones 2.4 mg  in each tablet.
Fig. 2. Analyses of blood pressure on 6 trials. Ginkgo biloba extract plus antihypertensive drugs vs antihypertensive drugs.Fig. 3. Analyses of systolic blood pressure on 3 trials. Ginkgo biloba e
Fig. 4. Analyses of diastolic blood pressure on 3 trials. Ginkgo biloba xtract plus antihypertensive drugs vs antihypertensive drugs.
extract plus antihypertensive drugs vs antihypertensive drugs.
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dverse effect
2 out of 9 included trials mentioned the adverse effect (Ge and
an 2008; Wang et al. 2012). 1 trial reported abdominal discom-
ort and loss of appetite in 6 cases (Wang et al. 2012). 1 trial
eported ﬂushing, dizziness and slight edema of the lower limbs
n both experimental and control group (Ge and Pan 2008). All of
he adverse events were not serious.
iscussion
This SR was initiated because GBE is often used by TCM physi-
ians and patients for the treatment of EH. Yet there is uncertainty
bout its clinical recommendation. In this review, 9 RCTs with 1012
articipants were included. Several trials demonstrated potential
ositive effect on BP reduction when compared with antihyperten-
ive drug therapy; however, it was not associated with a statistically
igniﬁcant effect on both SBP and DBP reduction in other 3 trials.
hat is more, methodological issues, small sample size, and signif-
cant heterogeneity of included trials did limit the extent to which
ny conclusions can be drawn. Therefore, as an adjunctive treat-
ent to antihypertensive drugs, the therapeutic effect of GBE for
H is still uncertain.
Inadequate reporting on adverse effects was also found in our
eview. It is widely accepted by part of patients and physicians that
atural herbal products are relatively safe for long term use with
ewer adverse effects as compared to antihypertensive drugs. How-
ver, in this review, only 2 studies with small simple size described
ild adverse events of GBE with spontaneous remission. Due to
he insufﬁcient data, it is too early to evaluate the safety of GBE for
H patients at present. Therefore, detailed description of adverse
vents in future studies of GBE is needed to conﬁrm the results.
The following limitations of this article should also be paid
ttention to. None of the included studies was assessed to be at
ow risk of bias. In our review, in fact, it was impossible to ﬁnd
ell-designed trials to evaluate efﬁcacy of GBE for the manage-
ent of EH. All the included trials had risk of bias in terms of design,
eporting, and methodology. Inadequate reporting of study design,
llocation sequence, allocation concealment, blinding, intention
o treat analysis and drop outs were provided in the most trials.
he main reasons are as follows: randomization was  mentioned
n all the trials; however, only 1 trial has described the concrete
ethods for random sequence generation, which might lead to
otential selection bias. Similar problem also exists in the trials
f Chen (2011), Yu (1999), Tu and Zhou (2007), Guo and Chen
2013) and Ge and Pan (2008). 5 trials mentioned above only had
ne or two authors. It is so difﬁcult to conduct a RCT properly in
erms of randomization procedure, allocation concealment, and
ouble-blind by them alone. Blinding is an essential method for
reventing research outcomes from being inﬂuenced by either the
lacebo effect or the observer bias (Smyth et al. 2011). However,
either blinding of participants and personnel nor blinding of out-
ome assessment is mentioned in all trials. Due to both researchers
nd patients being aware of the therapeutic interventions for the
ubjective outcome measures, the potential performance bias and
etection bias may  be generated. The placebo effect is another note-
orthy issue in TCM clinical studies (Kaptchuk 2002). Without a
igorous control for placebo effect, conclusions of these studies
ight be exaggerated because of nonspeciﬁc placebo effects (Brody
nd Miller 2011). However, no trial reported the application of
lacebo. Only 1 trial reported drop-out. Intention to treat analysis
as not applied in the vast majority of clinical trials. Most trials
ere small sample size and single-center. No trial has reported
 pre-trial estimation of sample size. Therefore, whether sample
ize meets the requirements of clinical research is still unknown.e 21 (2014) 1131–1136 1135
We  are not sure if they could provide enough power to detect the
difference between groups. What is more, due to the variations
in methodological quality, participants, intervention, and control,
signiﬁcant clinical heterogeneity was  found in our review, which
might weaken the reliability of the data statistics. Thus, we expect
that more RCTs of GBE will be appropriately designed, conducted,
and reported according to CONSORT statement and CONSORT state-
ment for herbal interventions.
Conclusion
There is no convincing evidence to support the routine use of
GBE for EH. More randomized trials with well design and adequate
sample size are warranted to generate high level of evidence thus
to support or refute the result in future.
Conﬂict of interest
None.
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